| Literature DB >> 31677966 |
Lehe Yang1, Shichong Lin2, Lingyuan Xu2, Jiayuh Lin3, Chengguang Zhao4, Xiaoying Huang5.
Abstract
Excessive activation of signal transducer and activator of transcription 3 (STAT3) signaling is observed in a subset of many cancers, making activated STAT3 a highly promising potential therapeutic target supported by multiple preclinical and clinical studies. However, early-phase clinical trials have produced mixed results with STAT3-targeted cancer therapies, revealing substantial complexity to targeting aberrant STAT3 signaling. This review discusses the diverse mechanisms of oncogenic activation of STAT3, and the small molecule inhibitors of STAT3 in cancer treatment.Entities:
Keywords: Activator; Cancer; Inhibitor; STAT3; Signal pathway
Mesh：
Substances：
Year: 2019 PMID： 31677966 DOI： 10.1016/j.cytogfr.2019.10.005
Source DB: PubMed Journal: Cytokine Growth Factor Rev ISSN： 1359-6101 Impact factor: 7.638